Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on May 8, 2019. The report discloses a material corporate governance event regarding the departure of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the resignation of Kamalam Unninayar from all positions with the Company, including her role as Chief Financial Officer (CFO). Her resignation is effective as of May 31, 2019.
Management Commentary and Risks
- Reason for Departure: The Company explicitly states that Ms. Unninayar did not resign for any reasons related to the Company's accounting practices or financial statements.
- Succession Plan: The Company has initiated a search for Ms. Unninayar's successor as CFO.
- Risks: No specific financial risks or contingencies are detailed in this filing beyond the operational impact of the CFO vacancy.
Investor Verification Checklist
- Confirm the effective date of the CFO resignation (May 31, 2019).
- Monitor subsequent filings for the appointment of an interim or permanent CFO.
- Review the most recent 10-Q or 10-K for the latest financial metrics, as this 8-K contains none.
- Verify that no other undisclosed issues related to accounting practices exist, given the specific denial in the filing.